How to Read a Women's Microbiome Supplement Label Before You Buy

Why one checklist is not enough for a women's formula

Most articles about reading supplement labels were written for the sports-nutrition aisle. They explain proprietary blends, they explain CFU counts, and they explain them separately. A women's microbiome formula is a harder object, because it is usually two different product categories fused into one capsule.

On one side are live bacteria, where the meaningful numbers are a strain code and a colony-forming-unit count that survives to the date on the bottle. On the other are botanical extracts, where the meaningful number is a standardised active compound — milligrams of proanthocyanidins, not milligrams of cranberry. The two halves fail in different ways, and a label can look generous on one while telling you nothing on the other.

So run the probiotic rows and the botanical rows separately, then look at the whole. A formula that passes six of twelve is not "half good" — it depends entirely on which six.

The 12-point label audit

Hold this against the bottle or the Supplement Facts panel. Each row is one yes-or-no question, and the red-flag column is the wording that usually signals a no.

What the CFU number actually has to clear

The reason row 2 and row 3 exist is a laboratory audit that almost no consumer page cites. In 2019, Di Pierro and colleagues bought nine commercial products from the Italian and French markets — seven dietary supplements and two medical devices — each of which declared at least one strain of Lactobacillus crispatus, and cultured what was actually in them.

Their headline conclusion, stated plainly in the paper: out of nine products, only two definitely contained viable L. crispatus cells at a daily dose of at least 1 × 10⁹ CFU per gram with acceptable correspondence to the label. Of those two, only one was formulated with a strain that had any documented scientific literature behind it.

Counts are total viable cells across all declared species on MRS medium, reported by the authors as log₁₀ CFU/g; a value of 9.0 is one billion CFU per gram, and each whole number is a tenfold difference. Presence of L. crispatus specifically was assessed on selective medium. Source: Di Pierro et al., Microorganisms 2019.

Three things fall out of that table. First, the spread is not marginal — product G returned a total viable count around 10² CFU per gram while product I returned around 10¹¹, nine orders of magnitude between two products on the same kind of shelf. Second, a product can carry a respectable total count and still contain no viable L. crispatus, because the total is a sum across every species in the blend. That is exactly why row 2 asks for a per-strain figure, and why a large total is not the reassurance it looks like — the argument in full is in why a bigger CFU count is not a better probiotic. Third, and most usefully: eight of the nine declared strain codes returned nothing in the published literature. A strain code is necessary but not sufficient — the point of having one is that you can go and search it.

The benchmark itself, at least 1 × 10⁹ CFU per gram per day, lines up with the labelling guidance from the International Scientific Association for Probiotics and Prebiotics. ISAPP asks manufacturers to declare genus, species and strain for each organism, and the minimum viable count of each strain at the end of shelf life. It advises consumers to avoid products stating a count at time of manufacture, because that number does not account for die-off. Row 3 is a direct restatement of that advice.

What the botanical number has to clear

The probiotic half of a women's formula fails by vagueness. The botanical half fails by substitution: a big, reassuring number is printed that is not the number the research used.

Cranberry is the clearest case. The compounds studied are the proanthocyanidins — PACs — and a milligram of cranberry extract is not a milligram of PAC. Two capsules can both say "cranberry extract 500 mg" and differ several-fold in PAC content, so the extract weight tells you almost nothing.

There is a threshold worth measuring against. A 2024 meta-analysis in Frontiers in Nutrition by Xiong and colleagues pooled 10 randomised controlled trials covering 2,438 participants and split them by PAC dose. At 36 mg a day or more, the pooled risk ratio was 0.82 (95% CI 0.69–0.98, p = 0.03). Below 36 mg a day, the result was not statistically significant (p = 0.39). In female-only cohorts the figure was RR 0.84 (95% CI 0.71–0.98, p = 0.02).

Read that as a labelling instruction, not a health promise: the number deciding whether a cranberry ingredient resembles the trials at all is a PAC figure, and 36 mg is the line. A label without one is not necessarily a weak product — it is an unverifiable one. For what cranberry and Lactobacillus do and do not show in trials, see our evidence review of cranberry and Lactobacillus for women's urinary health.

The proprietary blend rule, in one paragraph

Row 8 deserves an explanation, because a proprietary blend is not a loophole — it is written into the rules. Under US dietary supplement labelling regulations, a manufacturer using a proprietary blend must identify it as such, declare the total weight of the blend, and list the ingredients inside it in descending order of predominance by weight. It does not have to declare how much of each individual ingredient is in there. That is legal and common. The consequence is that with a blend you have only a total and a ranking: an ingredient sitting fourth in a 450 mg blend could be 200 mg or 2 mg, and nothing on the label distinguishes those two products. That matters most for the ingredients with the least behind them, such as the one we examine in the mimosa pudica seed evidence check.

Scoring a real product: FemiCore against the twelve rows

A checklist nobody applies is a decoration, so here is the product this site covers, scored honestly. FemiCore is a once-daily capsule containing four botanicals — cranberry extract, bearberry (uva-ursi) leaf, berberine and mimosa pudica seed — plus a five-strain Lactobacillus blend of L. crispatus, L. acidophilus, L. gasseri, L. plantarum and L. casei.

Score: 2 clear passes, 4 partials, 5 fails, 1 not assessable. That is a middling result on the numeric checks and a genuinely strong one on identity. The supplement facts panel codes all five strains and standardises the cranberry to 30 percent proanthocyanidin, which is more than a large share of the category does, and strain identity is the row hardest to fake. But the fails cluster in one place: the amounts. The panel prints two blend totals — Herbal Blend 350 mg and Probiotic Blend 50 mg — and no per-ingredient weight inside either, so there is no cranberry milligram figure to apply the 30 percent to, and no CFU count appears on the panel or on the manufacturer's sales page.

We are an affiliate publisher, and it would be easier to skip that paragraph. It is here because it is the honest output of the checklist — and because a reader applying these twelve rows across the category will reach much the same conclusion about most of it.

What this checklist does not show

Being straight about the limits of the method matters as much as the method.

A full label is not a working product. Every row above tests disclosure, not effect. A product could publish strain codes, per-strain CFU at expiry and a 40 mg PAC figure and still do nothing useful for a given person. Disclosure buys the ability to compare a product to the research; it does not transfer the research's results onto the product.

A missing number is not proof of a low dose. An undisclosed PAC content might be 50 mg or 5 mg. The failure is that you cannot tell, and a buyer should price that uncertainty in rather than assume the worst or the best.

Ingredient evidence is not finished-product evidence. Nearly every multi-ingredient supplement on the market, including this one, has never been tested as a finished formula in a clinical trial.

The audit paper is small and regional. Di Pierro tested nine products from two European markets in 2019. It is the most directly relevant data on this question, and nine products is not a survey of a global category. Treat it as a strong warning, not a population estimate. Once a label passes these checks, the next question is whether the ingredient itself has evidence — which is what our guide to urinary support supplements for women sets out.

None of this is about treating anything. These are dietary supplements. Nothing above claims that any product diagnoses, treats, cures or prevents any condition, and label quality is no substitute for a clinician when there are symptoms to explain.

Frequently asked questions